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http://www.biomedcentral.com/1471-2407/14/153RESEARCH ARTICLE Open AccessKi-67 is a valuable prognostic predictor of
lymphoma but its utility varies in lymphoma
subtypes: evidence from a systematic meta-analysis
Xin He1†, Zhigang Chen2†, Tao Fu3, Xueli Jin1, Teng Yu1, Yun Liang1, Xiaoying Zhao1 and Liansheng Huang1*Abstract
Background: Ki-67 is a nuclear protein involved in cell proliferation regulation, and its expression has been widely
used as an index to evaluate the proliferative activity of lymphoma. However, its prognostic value for lymphoma is
still contradictory and inconclusive.
Methods: PubMed and Web of Science databases were searched with identical strategies. The impact of Ki-67
expression on survival with lymphoma and various subtypes of lymphoma was evaluated. The relationship between
Ki-67 expression and Diffuse Large B Cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL) was also investigated
after the introduction of a CD-20 monoclonal antibody rituximab. Furthermore, we evaluated the association between
Ki-67 expression and the clinical-pathological features of lymphoma.
Results: A total of 27 studies met the inclusion criteria, which comprised 3902 patients. Meta-analysis suggested that
high Ki-67 expression was negatively associated with disease free survival (DFS) (HR = 1.727, 95% CI: 1.159-2.571) and
overall survival (OS) (HR = 1.7, 95% CI: 1.44-2) for lymphoma patients. Subgroup analysis on the different subtypes of
lymphoma suggested that the association between high Ki-67 expression and OS in Hodgkin Lymphoma (HR = 1.511,
95% CI: 0.524-4.358) was absent, while high Ki-67 expression was highly associated with worse OS for Non-Hodgkin
Lymphoma (HR = 1.777, 95% CI: 1.463-2.159) and its various subtypes, including NK/T lymphoma (HR = 4.766, 95% CI:
1.917-11.849), DLBCL (HR = 1.457, 95% CI: 1.123-1.891) and MCL (HR = 2.48, 95% CI: 1.61-3.81). Furthermore, the pooled
HRs for MCL was 1.981 (95% CI: 1.099-3.569) with rituximab and 3.123 (95% CI: 2.049-4.76) without rituximab, while
for DLBCL, the combined HRs for DLBCL with and without rituximab was 1.459 (95% CI: 1.084-2.062) and 1.456
(95% CI: 0.951-2.23) respectively. In addition, there was no correlation between high Ki-67 expression and the
clinical-pathological features of lymphoma including the LDH level, B symptoms, tumor stage, extranodal site,
performance status and IPI score.
Conclusions: This study showed that the prognostic significance of Ki-67 expression varied in different
subtypes of lymphoma and in DLBCL and MCL after the introduction of rituximab, which was valuable for
clinical decision-making and individual prognostic evaluation.
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Lymphomas represent a highly heterogeneous group
of hematological malignancies that can be classified
into two major categories: Hodgkin lymphoma (HL)
and non-Hodgkin lymphoma (NHL). NHL can be fur-
ther classified into subgroups such as Diffuse Large B
Cell Lymphoma (DLBCL), Follicular Lymphoma (FL),
Mantle Cell Lymphoma (MCL), NK/T cell lymphoma
and so on [1]. Over the past decades, the incidence of
lymphoma has increased dramatically, with NHL be-
coming the seventh most common form of cancer in
the United States [2]. However, although prognostic
factors based on clinical-pathological characteristics
have been widely used in predicting survival of pa-
tients with NHL, including Ann Arbor staging and the
international prognostic index (IPI), the precisely sur-
vival predictors on the basis of biological markers are
still lacking [3]. Therefore, identifying more bio-
markers to precisely stratify the group of patients with
poorer outcome and thus formulate the individually
treatment regimens is necessary and urgent.
Ki-67, a nuclear nonhistone protein, is synthesized at
the beginning of cell proliferation, and it is expressed
in all phases of the cell cycle except during G0 phase
[4]. Its strict association with cell proliferation and its
co-expression with other well-known markers of prolif-
eration indicate a pivotal role in cell division. Ki-67 ex-
pression has been widely used in clinical practice as an
index to evaluate the proliferative activity of lymphoma.
However, the relationship between Ki-67 expression
and outcome with various subtypes of lymphoma are
still contradictory and inconclusive in various studies.
Some studies show that high Ki-67 expression corre-
lates with poorer survival rates, while others show no
association or the reverse results [5-10]. Moreover, the
finding that the predictive significance of some prog-
nostic factors changed following the introduction of a
CD-20 monoclonal antibody, rituximab, underscores
the necessity for revaluating the prognostic value of
predictive factors after the introduction of rituximab
[11,12]. Therefore, further investigation is necessary to
clearly delineate the relationship between Ki-67 expres-
sion and prognosis in lymphoma.
In this study, we performed a meta-analysis to ex-
plore the impact of Ki-67 expression on survival with
various subtypes of lymphoma including HL, DLBCL,
MCL, FL and NK/T cell lymphoma. In addition, the re-
lationships between Ki-67 expression and DLBCL and
MCL were investigated after the introduction of rituxi-
mab. Furthermore, we also evaluated the association
between Ki-67 expression and the clinical-pathological
features of lymphoma. The results of our study provide
valuable information for the prognosis evaluation and
clinical treatment regimen making in lymphoma.Methods
Literature search
PubMed and Web of Science databases were searched with
the following terms: “Ki67”, “Ki-67”, “MIB-1”, “lymphoma”
and “prognosis”. The most recent search update was 31
August 2013. After examining the titles and abstracts of
the relevant articles and excluding nonrelated articles, full-
text checking of resting articles was performed. The refer-
ences of all of the included articles were also evaluated to
find additional relevant studies.
Inclusion and exclusion criteria
Strict inclusion criteria were used in identifying eligible
studies. Studies were included if they met the following
requirements: (1) The study investigated the association
between Ki-67 expression in tumor samples and overall
survival (OS), disease free survival (DFS) or clinical-
pathological features of the lymphoma; (2) The study pro-
vided sufficient data that the hazard ratio (HR) of the OS
and the DFS or the odds ratio (OR) of the clinical-
pathological factors could be calculated along with the cor-
responding 95% confidence interval (CI) (3) The study used
immunohistochemistry (IHC) as a measurement technique
(this criterion was implemented to avoid discrepancies
resulting from use of different assay methods to measure
Ki67) (4) The study results were written in English.
Only research complying with all of the above inclu-
sion criteria was finally included in our meta-analysis.
Thus, reviews, case reports, editorials or letters to the
editor without original data were not included, and stud-
ies with detection methods such as polymerase chain re-
action (PCR) or techniques other than IHC, as well as
articles published in a language other than English were
excluded.
Data extraction and assessment of study quality
Two primary investigators (CZG and FT) independently
conducted data extraction on the basis of the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [13]. Any discrepancies
were resolved by reviewing the study together and
reaching a consensus. The following information was re-
trieved from each study: first author, year, country, age
of patients, disease subtype, treatment regimen, number
of total cases and number of high Ki-67 expression and
low Ki-67 expression patients, high Ki-67 expression
threshold, study design, HR (95CI%) of OS or DFS and
clinical-pathological data. The quality of each study in-
cluded in our meta-analysis was assessed according to
the Newcastle–Ottawa quality assessment scale [14].
Statistical analysis
We calculated the pooled HRs and the 95% CI (confidence
interval) to analyze the aggregated impact of Ki-67
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the DFS and OS were counted. Moreover, subgroup ana-
lyses were also conducted based on the various subtypes
of lymphoma. HRs and their 95% CI were calculated using
the extracted data with the methods described in Parmar’s
study [15]. Essentially, if the HR and the corresponding
95% CI were not reported directly, data were extracted
from the survival curve published in the article and then
estimated using Engauge Digitizer version 4.1 (http://
digitizer.sourceforge.net/). We also calculated the ORs
and their 95% CI to assess the correlation between Ki-
67 expression and the clinical-pathological features of
lymphoma, such as performance status (PS), IPI score,
stage, B Symptom, LDH level and extranodal site. An
observed HR > 1 indicates a worse survival prognosis
for the group with high Ki-67 expression, while an ob-
served OR < 1 implies unfavorable clinical features in
the high Ki-67 expression group. If the 95% CI not
crossing 1, the correlation of Ki-67 expression with sur-
vival or clinical-pathological features was considered
statistically significant.
The statistical heterogeneity between the trials in-
cluded in the meta-analysis was assessed by the Chi-
square based Q statistical test according to Peto’s
method [16]. Inconsistency was quantified using the
inconsistency index (I2) statistic. A p-value less than
0.10 for the Q-test indicates substantial heterogeneity
among the studies. Random-effects or fixed-effects
models were used depending on the heterogeneity of
the included studies. In the presence of substantial het-
erogeneity, the pooled ORs and HRs were calculatedFigure 1 Flow diagram of the relevant studies selection procedure.by the random-effects model (the DerSimonian and
Laird method) [17]. Otherwise, the fixed-effects model
(the Mantel-Haenszel method) was used [18]. Egger’s
test was used to detect possible publication bias and
publication bias was supposed to exist when Egger’s
test yielded a p value <0.05. All calculations were per-
formed by STATA version 12.0 software (Stata Corpor-
ation, Collage Station, Texas, USA). A two-tailed P value
of less than 0.05 was considered statistically significant.
Results
Literature search and study characteristics
We identified 539 potentially relevant articles through
the search strategy presented in Figure 1. After screening
on the basis of abstracts or titles and then reviewing
full-text, 511 studies were excluded. Thus, 28 eligible
studies were finally included in this systematic review
and meta-analysis [5-10,19-40].
The details of the 28 studies are shown in Table 1. A
total of 4112 patients were enrolled in these studies which
were published between 1990 and 2013. Of these 28 stud-
ies, 5 each were conducted in America, 4 in Spain, 3 in
Korea, one each in Italy China, Germany, Canada, Czech,
Sweden, Poland, Japan, Egypt and Finland, and the rest 6
studies were conducted in Europe including many coun-
tries. 11 studies were prospective, while 17 were retro-
spective. The subclasses of lymphoma studied are as
follows: HL was studied in 3 articles and NHL was in 25
articles. Of the 25 articles investigating NHL, 12 focused
on DLBCL, 9 on MCL, 2 on NK/T cell lymphoma, and 2
articles examined various lymphoma subtypes.
Table 1 Characteristics of studies included in the final meta-analysis of Ki-67 expression and prognosis of lymphoma
First
author


















Salek 2013 [40] Czech 210 (74/136) NA MCL 30% (estimated) Anti-MIB-1 WTS From no chemotherapy
to intensive induction
with or without ASCT
2.05 (1.45-2.89) NA 7 R
R-treated 2.63 (1.72-4.04) NA
Li 2013 [5] America 43 (18/25) 46 median NK/TL 60% (image analysis) Anti-Ki-67 WTS CHOP + RT mostly 5.15 (1.52-17.58) 3.43 (1.1-10.72) 6 R
Geisler 2012 [6] Europe 122 (33/89) 56 median MCL 33% (estimated) NA NA R-CHOP/R-AraC + ASCT 2.64 (1.46-4.77) 2.32 (1.39-3.89) 7 p
Li 2012 [7] China 118 (55/63) 53 median DLBCL 70% (estimated) Anti-Ki-67 WTS R-CHOP + RT 1.284 (1.075-1.535) 3.38 (1.64-6.93) 8 R
Salles 2011 [19] Europea
and
America
1138 (627/511) NA DLBCL 75% (estimated) NA TMAs R-CHOP 1.8 (1.1-2.9) NA 8 p
CHOP 1 (0.6-1.5) NA
Gaudio 2011 [20] Italy 111 (38/73) 60 median DLBCL 80% (estimated) NA WTS R-CHOP 2.1 (1.6-4.8) 2.6 (1.2-3.8) 6 R
CHOP 2.1 (0.9-4.3) NA
Song 2011 [21] Korea 65 (31/34) 59 median DLBCL 70% (estimated) Anti-Ki-67 WTS HD-MTx +WBRT 1.657 (0.893-3.259) NA 5 R
Ott 2010 [22] Europe 386 (283/103) 68 median DLBCL 75% (estimated) Anti-MIB-1 TMAs R-CHOP 0.8 (0.4-1.5) 0.8 (0.5-1.4) 7 P
CHOP 1.1 (0.6-1.9) 0.9 (0.5-1.4)
Barros 2010 [23] Germany 87 (53/34) 14 median HL 50% (image analysis) Anti-MIB-1 TMAs ABVD + RT NA NA 7 R
Goy 2010 [8] Europea
and
America
67 (16/51) 66 median MCL 50% (estimated) Anti-Ki-67 WTS Bortezomib 1.93 (0.9-4.1) NA 5 P
Yoon 2010 [24] Korea 144 (46/98) 54 median DLBCL 85% (estimated) Anti-Ki-67 WTS R-CHOP + partial RT 2.876 (0.972-8.508) 2.9 (1.26-6.7) 9 P
Chung 2010 [25] Canada 80 (22/58) 64 median MCL 50% (estimated) Anti-Ki-67 WTS CHOP mostly 4.4 (2.24-8.64) NA 4 R
Garcia 2008 America 76 (38/38) 62 median MCL 20% (estimated) Anti-Ki-67 WTS R-hyper-CVAD NA NA 9 P
His 2008 America 52 (17/35) 56 median MCL 35% (estimated
and image analysis)
Anti-Ki-67 WTS R-CHOP + ASCT NA 2.46 (1.14-5.31) 9 P
Hasselblom 2008 [10] Sweden 199 (149/50) 66 median DLBCL 49% (image analysis) Anti-Ki-67 WTS CHOP/CHOP like +
partial RT
0.625 (0.256-1.11) NA 8 P
Szczuraszek 2008 [28] Poland 53 (24/29) 56.3 mean NHL 30% (image analysis) Anti-MIB-1 WTS NR 2.567 (1.144-5.761) NA 6 R
Determann 2008 [29] Europe 249 (nr) NA MCL 10% (estimated) Anti-MIB-1
or Ki-S5
NA CHOP or MCP or R-
CHOP
1.27 (1.15-1.39) NA 6 P
Kim 2007 [30] Korea 50 (27/23) 41 median NK/TL 65% (estimated) Anti-MIB-1 WTS CHOP + partial RT 4.33 (1.108-16.918) 3.23 (1.07-9.72) 8 R
Bahnassy 2006 [31] Egypt 50 (35/15) 45 median NHL 30% (estimated) Anti-MIB-1 WTS CHOP + partial RT 0.696 (0.274-1.766) NA 7 R
Jerkeman 2004 [9] Europe 185 (69/116) NA DLBCL 60% (estimated) Anti-MIB-1 WTS CHOP or M-BACOP 0.56 (0.3-1) 0.53 (0.31-0.91) 5 P
Martinez 2004 [32] Spain 80 (nr) NA MCL 50% (estimated) Anti-MIB-1 WTS NA 4.4 (1.9-9.9) NA 4 R


















Table 1 Characteristics of studies included in the final meta-analysis of Ki-67 expression and prognosis of lymphoma (Continued)
Provencio 2003 [34] Spain 42 (nr) 29mean HL 20% (NA) NA WTS MOPP or ABVD 3.3 (0.85-12.5) 2.21 (0.92-5.33) 4 R
Raty 2002 [35] Finland 96 (31/65) NA MCL 26% (estimated) Anti-Ki-67 WTS CHOP or M-BACOD
mostly + partial RT
and SCT
3.25 (1.9-5.58) NA 5 R
Sanchez 1998 [36] Spain 77 (36/41) 62 median DLBCL 20% (image analysis) Anti-MIB-1 WTS CHOP + partial RT
or surgery
1.74 (1.064-2.848) 1.06 (0.48-2.33) 6 R
Morente 1997 [37] Spain 140 (nr) NA HL Continuous variable
(image analysis)
Anti-MIB-1 WTS MOPP or ABVD + RT 1.04 (1–1.08) NA 4 R
Miller 1994 [38] America 60 (11/49) NA DLBCL 80% (estimated) Anti-Ki-67 WTS CHOP, M-BACOD,
ProMACE-CytaBOM,
or M-BACOP
5.9 (2.2-16.1) NA 8 P
Slymen 1990 [39] America 105 (19/86) 58 median DLBCL 60% (estimated) Anti-Ki-67 WTS CHOP, M-BACOD,
ProMACE-CytaBOM,
CVP or M-BACOP +
partial RT or surgery
3.64 (1.66-7.95) NA 8 R
P/N, the number of positive/negative; NK/TL. NK/T cell lymphoma; MCL, mantle cell lymphoma; DLBCL, difftuse largeB-cell lymphoma; NHL, Non Hodgkin Lymphoma; HL, Hodgkin Lymphoma; NA, not availiable; WTS,
whole tissue sections; TMAs, tissue microarrays; HR, hazard ratio; 95CI%, 95% confidence interval; OS, overall survival; DFS, disease free survival; P, prospective; R, retrospective; R-CHOP, rituximab, cyclophosphamide,
doxorubicin, vincristine and prednisone; RT, radiotherapy; ASCT, autologous stem cell transplantation; WBRT, Whole Brain Radiotherapy; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; R-hyper-CVAD,
rituximab plus hyperfractioned cyclophosphamide, vincristine, doxorubicin, and dexamethasone; MCP, mitoxantrone, chlorambucil, and prednisone; M-BACOD(P), methotrexate, bleomycin, doxorubicin, cyclophospha-mide,
vincristine, dexamethasone (prednisone); MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; ProMACE-CytaBOM, doxorubicin, cyclophosphamide, etopo-side, cytarabine, bleomycin, vincristine, methotrexate
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OS and 11 provided the HR of the DFS directly or indir-
ectly. Three studies investigated the relationship between
Ki-67 expression and the survival from DLBCL in two
distinct groups, one group with rituximab and one with-
out. Thus, the HR of OS or DFS could be calculated
separately for each group and information could be ob-
tained regarding how rituximab influences the relation-
ship between Ki67 expression and prognosis.
Methodological quality of the studies
The quality of the 28 studies, including case–control
and cohort studies, was evaluated based on the Newcas-
tle–Ottawa scale (NOS). The NOS scoring system con-
sists of three components: selection, comparability, and
exposure or outcome. The quality scores for selected
studies ranged from 4 to 9, and the median score was 6.
Fourteen studies (eight prospective and six retrospective)NOTE: Weights are from random effects analysis






























Figure 2 The hazard ratio (HR) of Ki-67 expression associated with th
high Ki-67 expression.were ranked ‘high quality’, meaning that they scored
higher than a six (Table 1).Impact of high Ki-67 expression on the survival of
lymphoma and the subgroup and the sensitivity analyses
The pooled HRs of the OS provided in 24 articles was
1.7 (95% CI: 1.44-2, p = 0.000) (Figure 2) with hetero-
geneity (I2 82.7% P = 0.000), and the combined HRs
of the DFS in 11 articles was 1.727 (95% CI: 1.159-
2.571, p = 0.007) (Figure 3) with heterogeneity (I2 75.2%
P = 0.000). In both cases, the results demonstrate that high
Ki-67 expression is negatively associated with the survival
prognosis of lymphoma.
Subgroup analysis of OS was performed according to
publication era, study location, number of patients, posi-
tive threshold, quality score and study design (Table 2).
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Figure 3 The hazard ratio (HR) of Ki-67 expression associated with the disease free survival (DFS). HR > 1 indicated worse DFS for the
group with high Ki-67 expression.
Table 2 Stratified analysis of the pooled hazard ratio (HR) for the associations of high Ki-67 expression with overall
survival (OS) of lymphoma
Heterogeneity
Stratified analysis Number of studies Number of patients Pooled HR(95% CI) P value I2(%) P value
Publication era
Published in 21st 20 3488 1.689(1.386-2.057) 0.000 72.7% 0.000
Published in 20th 4 382 1.671(1.41-1.98) 0.000 88,2% 0.000
Study location
Europe and America 19 3443 1.749(1.447-2.114) 0.000 84.9% 0.000
Asia 4 377 1.694(1.089-2.635) 0.019 44.1% 0.147
Number of patients
≥100 12 2394 1.35(1.144-1.593) 0.00 80.8% 0.000
<100 12 1476 2.663(1.923-3.687) 0.000 49.3% 0.027
High expression threshold
≥50% 14 2332 1.906(1.429-2.543) 0.000 73.4% 0.000
<50% 9 1098 1.722(1.238-2.395) 0.001 76.2% 0.000
Quality score
≥7 11 2582 1.584(1.188-2.112) 0.002 70.9% 0.000
<7 13 988 1.815(1.451-2.271) 0.000 85.9% 0.000
Study design
P 9 2550 1.336(1.001-1.782) 0.049 70.8% 0.000
R 15 1320 2.144(1.628-2.824) 0.000 85.8% 0.000
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http://www.biomedcentral.com/1471-2407/14/153between high Ki-67 expression and OS was present
across all strata.
The outcome of sensitivity analysis of OS showed that
the gathered HR ranged from 1.67 (95% CI: 1.4 – 1.99)
to 1.87 (95% CI: 1.49 – 2.35) after removing the study of
Chung et al. and the study of Determann et al. respect-
ively (Table 3). It suggested that the negative association
between high Ki-67 expression and prognosis of lymph-
oma existed after excluding anyone study.
Correlation of high Ki-67 expression with the OS of the
subtypes of lymphoma
Of the 24 articles investigating the association between
Ki-67 expression and OS, 2 examined Hodgkin Lymph-
oma and 23 examined Non-Hodgkin Lymphoma. The
overall HRs for Hodgkin Lymphoma was 1.511 (95%
CI: 0.524-4.358, p = 0.445), with heterogeneity (I2 64.7%
P = 0.092), and for Non-Hodgkin Lymphoma, it was
1.777 (95% CI: 1.463-2.159, p = 0.000), with heterogen-
eity (I2 74.3% P = 0.000) (Table 4). A subsequent sub-
type analysis of NHL was performed. The pooled HRs
for DLBCL, MCL and NK/TL were 1.457 (95% CI:Table 3 Summary estimates of the hazard ratio (HR) and 95%
meta-analysis
Study omitted Estimated HR
Slymen (1990) [39] 1.6952128
Miller (1994) [38] 1.6858797
Morente (1997) [37] 1.8667241
Sanchez (1998) [36] 1.7437564
Raty (2002) [35] 1.6774691
Provencio (2003) [34] 1.7260282
Jerkeman (2004) [9] 1.8312747
Martinez (2004) [32] 1.6864121
Bahnassy (2006) [31] 1.7862245
Kim (2007) [30] 1.7185497
Hasselblom (2008) [10] 1.8081217
Szczuraszek (2008) [28] 1.7200329
Determann (2008) [29] 1.8672591
Ott (2010) [22] 1.8099216
Goy (2010) [8] 1.7372652
Yoon (2010) [24] 1.7240045
Chung (2010) [25] 1.6677585
Salles (2011) [19] 1.7680753
Gaudio (2011) [20] 1.7206854
Song (2011) [21] 1.7479872
Geisler (2012) [6] 1.7052457
Li (2012) [7] 1.8065342
Li (2013) [5] 1.7072812
Salek (2013) [40] 1.71729971.123-1.891, p = 0.005), 2.48 (95% CI: 1.61-3.81, p = 0.000)
and 4.766 (95% CI: 1.917-11.849, p = 0.001) respectively
(Table 4).
Correlation of high Ki-67 expression with the introduction
of rituximab
The effect of rituximab treatment on the association be-
tween the Ki-67 expression and the OS was also evaluated
for DLBCL and MCL. The combined HRs for DLBCL
with rituximab was 1.459 (95% CI: 1.084-2.062, p = 0.014),
compared to 1.456 (95% CI: 0.951-2.23, p = 0.084) for
DLBCL without rituximab (Figure 4, Table 4). In contrast,
with MCL, the prognostic significance of Ki-67 expression
was not changed after the introduction of rituximab; the
pooled HRs was 1.981 (95% CI: 1.099-3.569, p = 0.023)
with rituximab and 3.123 (95% CI: 2.049-4.76, p = 0.000)
without rituximab (Figure 5, Table 4).
Association between high Ki-67 expression and
clinical-pathological characteristics of lymphoma
Overall, there was no correlation between high Ki-67
expression and the clinical-pathological features ofCI of sensitivity analysis of overall survival (OS) for the

























NOTE: Weights are from random effects analysis
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Figure 4 The hazard ratio (HR) of Ki-67 expression associated with the overall survival (OS) of DLBCL following and without following
rituximab treatment. HR > 1 implied worse OS for the group with high Ki-67 expression.
He et al. BMC Cancer 2014, 14:153 Page 9 of 13
http://www.biomedcentral.com/1471-2407/14/153lymphoma. Ten studies investigated the association of
high Ki-67 expression with the LDH level and B symp-
toms. The pooled ORs were 0.914 (95% CI: 0.673-1.241,
P = 0.564) and 0.851 (95% CI: 0.557-1.3, P = 0.455) for
LDH level and B symptoms respectively (Table 5). To
analyze the correlation of Ki-67 expression with tumor
stage and the extranodal site, nine studies were used.
The aggregated ORs were 1.089 (95% CI: 0.79-1.501,
P = 0.604) for tumor stage and 1.017 (95% CI: 0.674-
1.534, P = 0.937) for extranodal site (Table 5). Finally,
seven studies evaluated the correlation of high Ki-67 ex-
pression with performance status and IPI score. The com-
bined ORs were 1.082 (95% CI: 0.654-1.793, P = 0.758) for
performance status and 0.963 (95% CI: 0.667-1.39, P =
0.84) for IPI score, revealing no correlation for either
clinical-pathological feature (Table 3).Publication bias
Egger’s test showed no publication bias for high Ki-67
expression with regard to OS, DFS and the clinical-
pathological features of lymphoma. Figure 6 provides a
funnel plot for the study on the effects of high Ki-67 ex-
pression on the OS of lymphoma.Discussion
Ki-67 is a nuclear nonhistone protein first identified in
1991 by Gerdes et al. [41]. Because it is expressed in all
phases of the cell cycle except the resting stage (G0), it
has been used as a proliferation marker in numerous
cancers including lymphoma [38,42,43]. Nonetheless,
studies examining the relationship between Ki-67 ex-
pression and prognosis with lymphoma have been incon-
clusive. In this study, we conducted a meta-analysis that
pooled data from all of the relevant studies to explore
the correlation between Ki-67 expression and the sur-
vival outcome in lymphoma. The results revealed that
high Ki-67 expression in patients with lymphoma was
associated with worse prognosis, both for the OS (HR =
1.7, 95% CI: 1.44-2; P = 0.000) and DFS (HR = 1.727, 95%
CI: 1.159-2.571; P = 0.007). Sensitivity analysis suggested
that the association between high Ki-67 expression and
prognosis of lymphoma was stable and not changed after
removing anyone study. Additionally, when subgroup
analysis was performed according to study design, the
prospective studies which exhibited more powerful sta-
tistics still showed a statistically significant prognostic
value for Ki-67 expression in lymphoma (HR = 1.336,
95% CI: 1.001-1.782; P = 0.049).
Table 4 Summary estimates of the hazard ratio (HR) for the associations of high Ki-67 expression with overall survival
(OS) of subtypes of lymphoma
Heterogeneity
Subtypes of lymphoma Number of studies Number of patients Pooled HR(95% CI) P value I2(%) P value
HL 2 162 1.511(0.524-4.358) 0.445 64.7% 0.092
NHL 22 3708 1.777(1.463-2.159) 0.000 74.3% 0.000
DLBCL (total) 11 2588 1.457(1.123-1.891) 0.005 67.7% 0.000
DLBCL (with rituximab) 5 753 1.495(1.084-2.062) 0.014 52.3% 0.078
DLBCL (without rituximab) 9 1835 1.456(0.951-2.23) 0,084 74.8% 0.000
MCL (total) 7 904 2.48(1.61-3.81) 0.000 85.6% 0.000
MCL (with rituximab) 3 581 1.981(1.099-3.569) 0.023 87.4% 0.000
MCL (without rituximab) 3 243 3.123(2.049-4.76) 0.000 21.8% 0.278
NK/TL 2 93 4.766(1.917-11.849) 0.001 0% 0.853
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http://www.biomedcentral.com/1471-2407/14/153Lymphoma is a type of hematological malignancy
displaying substantial heterogeneity, and the clinical and
biological characteristics of the different subtypes vary
greatly. In our meta-analysis, the outcome of further ana-
lyzing the association between Ki-67 expression and the
prognosis of various subtypes of lymphoma supported it.
High Ki-67 expression was a valuable prognostic indicatorNOTE: Weights are from random effects analysis
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and its various subtypes such as DLBCL, MCL and
NK/TL, but not for HL (HR = 1.511, 95% CI: 0.524-
4.358, P = 0.445).
The development of new therapeutic agents, such as
rituximab, that target specific molecules, has greatly im-
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Table 5 Summary estimates of the odds ratio (OR) for the associations of High Ki-67 expression and
clinical-pathological features of lymphoma
Heterogeneity
Clinicopathological features Nuber of studies Nuber of patients Pooled OR(95% CI) P value I2(%) P value
Performance status (0–1 vs.2-5) 7 643 1.082(0.654-1.793) 0.758 31.7 0.186
Elevated LDH (normal vs. elevated) 10 884 0.914(0.673-1.241) 0.564 36.6 0.115
IPI score (0–2 vs.3-5) 7 611 0.963(0.667-1.39) 0.84 0 0.53
Tumor stage (I-II vs. III-IV) 9 845 1.089(0.79-1.501) 0.604 37.4 0.119
B symptom (no vs. yes) 10 944 0.851(0.557-1.3) 0.455 45 0.059
Extranodal site (no vs. yes) 9 758 1.017(0.674-1.534) 0.937 20.7 0.259
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http://www.biomedcentral.com/1471-2407/14/153the cancer statistics provided by American Cancer Soci-
ety in 2012, the 5-year survival rate of NHL has im-
proved from 47% in 1970s to 70% in recent years, and
rituximab has been central to this improved prognosis.
[2]. However, it is important to realize that after treat-
ment with rituximab, many widely used and validated
prognostic factors no longer remain significant in
lymphoma [11,12]. Ann Arbor stage III-IV, age, B symp-
toms and serum LDH level, which predict survival in
chemotherapy groups not taking rituximab, are no lon-
ger accurate predictors in chemotherapy groups taking
rituximab. In our study, owing to the limited data, we
only analyzed the effect of rituximab on the prognostic
significance of Ki-67 expression in DLBCL and MCL. In
DLBCL, without rituximab, Ki-67 expression was not
related to OS rates, consistent with the results of the
Nordic Lymphoma Group Study and other additional stud-
ies [9,20-22]. However, the prognostic value of Ki-67 ex-
pression in DLBCL became significant following rituximab
treatment (HR = 1.459, 95% CI: 1.084-2.062, p = 0.014). A
recent large prospective study from the Lunenburg
Lymphoma Biomarker Consortium including 2451 patientsFigure 6 Funnel plot of Ki-67 expression and the overall survival (OS)also identified high Ki-67 expression as a good predictive
factor in DLBCL with rituximab, which is consistent with
our findings [19]. In MCL, the difference was observed:
high Ki-67 index was related to a poor OS with rituximab
(HR = 1.981, 95% CI: 1.099-3.569, p = 0.023), and was also
correlated with survival outcome without following rituxi-
mab treatment (HR = 3.123, 95% CI: 2.049-4.76, p = 0.000).
Though our study yielded important results regarding
the prognostic value of Ki-67 expression in lymphoma,
some limitations existed in our meta-analysis. First, al-
though subgroup analysis adjusted for the cut-off point
was conducted and no changing of the prognostic value
of Ki-67 was found, the heterogeneity caused by the dif-
ferent cut-off point of high Ki-67 expression was inevit-
ably. Therefore, the high inter-observer variability still
restricts the use of the Ki-67 index in experimental as
well as clinical practice relatively. Spyratos et al. sug-
gested to choose the cut-off point according to the clin-
ical objective [44]. That is: to exclude patients with
slowly proliferating tumors, low cut-off point should be
set to avoid overtreatment, while high cut-off point is
suitable to be used to identify patients sensitive toof lymphoma for the assessment of publication bias.
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http://www.biomedcentral.com/1471-2407/14/153chemotherapy schedule. However, an optimal cut-off
point needs to be defined and validated for lymphoma
further. Second, we were unable to evaluate the relation-
ship between Ki-67 expression and the treatment out-
come due to the limited data. This is important, as
some authors speculate that the association between
high Ki-67 expression and poor prognosis in lymphoma
results from regrowth of tumors or an increased likeli-
hood of future mutations, leading to treatment failure,
whereas others suggest that high proliferative activity,
represented by high Ki-67 expression, may be more
sensitive to chemotherapy and thus more likely to re-
spond well to treatment[9,30,45]. Therefore, it would
be interesting to investigate the correlation between
high Ki-67 expression and the treatment outcome to
clarify the mechanism of Ki-67 action. In addition, an-
other limitation was the inability to evaluate certain
subtypes of lymphoma due to the paucity of studies re-
lated to them.
Conclusion
Despite these limitations, this meta-analysis supports the
prognostic value of Ki-67 in lymphoma, demonstrating a
significant correlation between high Ki-67 expression
and a poor survival outcome. However, this association
exists in the NHL subtypes, including DLBCL, MCL, NK/
TL, but not in HL. In addition, in DLBCL, Ki-67 expres-
sion has prognostic value following rituximab treatment
but the prognostic value diminishes without following ri-
tuximab treatment, while in MCL, the prognostic value of
Ki-67 expression exists whether or not following rituxi-
mab treatment. Thus, the prognostic significance of Ki-67
expression varies in different subtypes of lymphoma and
in DLBCL and MCL after the introduction of rituximab,
which is valuable for individual prognostic evaluation. Fur-
ther adequately designed prospective studies still need to
be conducted to verify our results.
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